688356.SH
键凯科技
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 124.00
+15.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 328.3M | 318.2M | 227.1M | 292.1M | 407.2M |
| Cost of Revenue | 110.1M | 116.6M | 69.9M | 54.8M | 61.7M |
| Gross Profit | 218.1M | 201.6M | 157.2M | 237.3M | 345.5M |
| Operating Expenses | |||||
| R&D Expense | 56.1M | 54.7M | 59.1M | 57.8M | 77.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 55.4M | 56.8M | 52.5M | 39.7M | 52.5M |
| Selling & Marketing Expense | 15.7M | 13.7M | 7.3M | 6.4M | 11.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 135.4M | 131.2M | 121.1M | 106.4M | 138.5M |
| Cost and Expenses | 245.5M | 247.8M | 191.0M | 161.2M | 200.2M |
| Operating Income (EBIT) | 82.3M | 69.9M | 33.8M | 127.0M | 209.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 81.2M | 69.2M | 32.7M | 126.2M | 207.7M |
| Income Tax Expense | 9.0M | 7.5M | 2.8M | 10.5M | 20.8M |
| Bottom Line | |||||
| Net Income | 72.2M | 61.7M | 29.8M | 115.7M | 186.8M |
| Earnings from Cont. Ops | 72.2M | 61.7M | 29.8M | 115.7M | 186.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 72.2M | 61.7M | 29.8M | 115.7M | 186.8M |
| Per Share | |||||
| Basic EPS | CN¥1.19 | CN¥1.02 | CN¥0.49 | CN¥1.92 | CN¥3.11 |
| Diluted EPS | CN¥1.19 | CN¥1.02 | CN¥0.49 | CN¥1.91 | CN¥3.08 |
| Revenue Per Share | CN¥5.42 | CN¥5.26 | CN¥3.73 | CN¥4.85 | CN¥6.78 |
| Shares | |||||
| Basic Shares Outstanding | 60.6M | 60.5M | 60.9M | 60.3M | 60.1M |
| Diluted Shares Outstanding | 60.6M | 60.5M | 60.9M | 60.3M | 60.1M |
| Profitability Metrics | |||||
| EBITDA | — | 113.5M | 77.8M | 156.3M | 230.8M |
| D&A | — | 43.6M | 44.0M | 29.4M | 21.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026